MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.4162
-0.0238
-5.41%
After Hours: 0.4100 -0.0062 -1.49% 18:41 11/13 EST
OPEN
0.4730
PREV CLOSE
0.4400
HIGH
0.4730
LOW
0.4104
VOLUME
95.06K
TURNOVER
--
52 WEEK HIGH
1.490
52 WEEK LOW
0.4100
MARKET CAP
5.91M
P/E (TTM)
-0.5950
1D
5D
1M
3M
1Y
5Y
1D
Aprea’s APR-1051 Advances with Encouraging Safety, Supporting Buy Rating and Unchanged $5 Price Target
TipRanks · 4d ago
Weekly Report: what happened at APRE last week (1102-1106)?
Weekly Report · 6d ago
Aprea Q3 Loss Widens On R&D Costs; Updated APR-1051 Phase 1 Data Due November 20
NASDAQ · 11/05 09:09
Aprea Therapeutics GAAP EPS of -$0.09 in-line
Seeking Alpha · 11/05 08:19
Aprea Therapeutics reports Q3 EPS (9c), consensus (8c)
TipRanks · 11/04 14:00
*Aprea Therapeutics 3Q Loss $4.81M >APRE
Dow Jones · 11/04 13:30
*Aprea Therapeutics 3Q Loss/Shr 9c >APRE
Dow Jones · 11/04 13:30
Press Release: Aprea Therapeutics Announces Third -2-
Dow Jones · 11/04 13:30
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.